Swiss Chems

Provider Profile Name: Swiss Chems
Website: swisschems.com
Founded: August 2018
Provider Type: Research Peptide Vendor
FDA Warning Letter: December 10, 2024

Operating Details

• E-commerce peptide vendor 
• Received an FDA warning letter in December 2024 after an investigation found the company was selling semaglutide and retatrutide products for human use despite marketing them for research and chemical purposes
• No prescription required for purchase
• Products sold as freeze-dried powders requiring reconstitution

About the Company

Swiss Chems was among the companies targeted in the FDA’s December 2024 enforcement wave, alongside Xcel Peptides, Summit Research, and Prime Peptides, all found to be selling semaglutide, tirzepatide, and/or retatrutide for human use despite marketing the drugs for research and chemical purposes.

Swiss Chems, a US-based retailer established in August 2018, specializes in health supplements, including SARMs, peptides, SERMs, prohormones, kratom, and CBD, operating with a direct-to-consumer model focused on research-grade supplements. The GLP-1 products Swiss Chems sells are a subset of a broader catalogue of research chemicals, and weight loss is not the platform’s primary business focus.

The FDA reviewed Swiss Chems’ website and social media pages and found evidence that the company was positioning its products to “prevent, treat, or cure disease conditions and/or affect the structure or function of the body” claims that establish human use intent and constitute violations of the Federal Food, Drug, and Cosmetic Act, regardless of “research only” disclaimers present on product pages.

Swiss Chems is among several companies that became prominent suppliers in the grey-market research peptide space, selling freeze-dried powder compounds that buyers reconstitute into injectable solutions operating under “research use only” disclaimers that regulators say are often largely theoretical given the evident consumer weight-loss and performance focus of the marketing.

GLP-1 Weight Loss

• Lose pounds of fat every week
• Money Back Guarantee
• No membership or hidden fees! Everything you need is included
• Start for just $179, no insurance required + free shipping

GLP-1 for Just $179

100k MembersHSA/FSA ApprovedFrom $179

The broader enforcement context: following the December 2024 warning letters, FDA enforcement against the grey-market peptide industry escalated substantially into 2025, including a warehouse raid of Amino Asylum in June 2025, DOJ involvement in warning letter enforcement, and criminal prosecutions resulting in guilty pleas and seven-figure forfeitures against multiple peptide industry participants.

Independent testing of products from vendors in this category has identified discrepancies between labeled and actual contents, including contamination and inaccurate dosages. This quality-control concern extends across the grey-market peptide ecosystem and is not unique to any single vendor.

GLP-1 Offerings and Pricing

Swiss Chems sells semaglutide, retatrutide, and potentially other GLP-1-class research peptides in lyophilized (freeze-dried) vial format. No prescription is required for purchase. No licensed prescriber reviews eligibility before or after purchase. No clinical oversight, dosing guidance, titration support, or patient safety monitoring is provided.

User-reported prices submitted to the weightlossinjections.com directory illustrate the substantial price differential between this vendor and licensed telehealth programs:

• Compounded tirzepatide 30mg: $62.69 (user-reported, sourced from a peptide comparison site)
• Compounded tirzepatide 10mg: $35.00 (user-reported, sourced from a peptide comparison site)
• Compounded semaglutide 3mg/1 vial: $170.10 (user-reported)

These prices are dramatically below licensed telehealth compounded GLP-1 programs, which typically run $149–$299/month all-inclusive. The cost differential reflects the absence of physician oversight, pharmacy accreditation, clinical safety infrastructure, quality assurance, and regulatory compliance. This does not represent superior value; it represents the removal of the entire safety framework that legitimate programs provide. 

Reviews from Trustpilot and Google

No approved patient reviews appear for Swiss Chems at the time of writing. No standalone Trustpilot or consumer health review pool was identified specifically for Swiss Chems’ GLP-1 products. Consumer discussion surfaces primarily through specialized peptide forums, Reddit communities, and biohacking platforms from participants self-identifying as researchers or biohackers rather than clinical weight management patients.

The regulatory enforcement action on record and the quality variability concerns documented across this vendor category are more clinically relevant to weight loss patients considering this vendor than any consumer review data.

Compounding Pharmacies Used

Swiss Chems is not a compounding pharmacy and does not operate through the 503A or 503B compounding pharmacy framework. Products are manufactured and sold as research chemicals with no disclosed manufacturing source, quality testing methodology, or pharmacy licensure verifiable by consumers. The manufacturing standards, sterility testing requirements, and regulatory oversight applicable to licensed compounding pharmacies do not apply here.

Note: Swiss Chems received an FDA warning letter on December 10, 2024 for selling unapproved GLP-1-class drugs including semaglutide and retatrutide — one of four simultaneous warning letters issued to grey-market peptide vendors that day. The FDA determined these products were intended for human therapeutic use despite “research only” labeling. Swiss Chems is not a telehealth provider, has no licensed prescriber network, and does not operate through licensed compounding pharmacies. User-reported prices in the directory ($35–$170 per vial) reflect research peptide pricing rather than clinical program pricing, and no clinical care structure exists around these products. Purchasing GLP-1-class peptides from research vendors without a prescription and without medical supervision carries significant safety risks. Patients seeking GLP-1 treatment should use a licensed telehealth provider with a board-certified prescriber and 503A or 503B pharmacy sourcing. Swiss Chems appears in this review series because it is listed in the weightlossinjections.com directory.